Advertisement

Picture AB Sciex Berliner LCMSMS Symposium 2017 Middle 600x60px
Document › Details

4-Antibody AG. (9/26/08). "Press Release: 4-Antibody Appoints Dr. Richard Mason as New Chief Executive Officer". Basel.

Organisations Organisation 4-Antibody AG
  Group Agenus (Group)
  Organisation 2 Advent Venture Partners (Advent Ltd.)
Products Product therapeutic antibody
  Product 2 MAb, human, fully
Person Person Mason, Richard (JnJ 201511– Head Innovation Centre London before XO1 + BTG + 4-Antibody + Advent Venture Partners + CAT)
     


4-Antibody AG today announced that Dr. Richard Mason has joined the company as Chief Executive Officer and Geschäftsführer. Dr. Mason joins 4-Antibody from venture capital firm Advent Venture Partners, an investor in 4-Antibody, where he has been an Executive-in-Residence.

Previously Dr. Mason was Senior Vice President Business Development at Cambridge Antibody Technology plc (CAT). As head of CAT's business development team he was responsible for numerous transactions with major pharmaceutical and biotechnology companies including leading the negotiation of the original antibody co-discovery and co-development agreement with AstraZeneca which subsequently led to AstraZeneca's acquisition of CAT for $1.3 billion.

Dr. Mason qualified in medicine from the Medical College of St. Bartholomew's Hospital, University of London. He trained in internal medicine and is a member of the Royal College of Physicians. He also holds a BSc degree in Immunology from University College London and an MBA from the Judge Business School, University of Cambridge.

"We are delighted to appoint Richard as our CEO to lead 4-Antibody through the next exciting phase of its growth. His organisational leadership skills and experience in commercial deal-making in the antibody space will be instrumental as we establish our technology as a new gold-standard for the discovery of fully human monoclonal antibody therapeutics" stated Prof. Dr. Max Burger, Chairman of 4-Antibody's Board.

Commenting on his appointment, Dr. Mason said, "I am very pleased to be joining this young and dynamic company with its world-class team of immunologists and molecular biologists. 4-Antibody has the most exciting and unencumbered platform for generating therapeutic antibodies in the industry today."

   
Record changed: 2016-03-20

Advertisement

Picture EBD Group BIO-Europe Spring 2017 BES Barcelona Spain March 600x60px

More documents for Agenus (Group)


To subscribe to our free, monthly newsletter for the life sciences in German-speaking Europe (DE, AT & CH), please send an e-mail to info@iito.de and simply fill the subject line with the word »LSG newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture Sacura e.tract software 2017 600x60px wpq




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture AB Sciex Berliner LCMSMS Symposium 2017 Right 120x80px Picture VIB Conferences Revolutionizing Next Gen Sequencing 2017 120x180px Picture BIO Deutschland Dt Biotechnologietage DBT 2017 Hannover April 120x240px Picture EBD Group BIO-Europe Spring 2017 BES Barcelona Spain March 120x180px Picture Sacura e.tract software 2017 120x240px wpctoc Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px